What Is the Difference Between Neurofeedback and TMS?

Direct Answer

They are grouped together as neuromodulation, and they work in opposite directions. Transcranial magnetic stimulation applies a magnetic field from outside the head to change activity in a targeted cortical region. The patient sits still and receives it. Neurofeedback measures the patient’s own brain activity, displays it back as sound or images and rewards shifts toward a target pattern, so the patient learns to change their own activity through repeated practice. One is a procedure delivered to a person and the other is a skill acquired by a person.

Almost every practical difference follows from that. TMS devices carry disease-specific FDA clearances while biofeedback devices are classified generically, by what the device does rather than by a condition it treats. Non-response to TMS means the intervention did not produce the effect, while non-response to neurofeedback may mean the client did not learn the regulation. And the evidence bases are structured differently, which is why comparing them by effect size alone is misleading.

The Patient’s Role Is the Actual Difference

Neurofeedback is built on operant conditioning. A review of EEG neurofeedback describes the mechanism as one in which the probability of a future response depends on its association with an immediately following consequence, with positive consequences increasing the likelihood of a given response.¹ The learner gradually establishes an internal target state and refines it by comparing actual against desired states across sessions.¹

That framing has an implication clinicians should carry into the referral conversation. Neurofeedback requires the client to learn something, and people differ in how readily they do. The same review notes that positive mood, motivation and locus of control have been identified as predictors of training success, that neuroanatomical features may also be associated with it and that in at least one study participants could not articulate the strategy they had used.¹ A client who is disengaged, demoralized or unable to attend consistently is a poorer candidate for a learning-based intervention than for a procedural one.

TMS asks nothing comparable of the patient. A standard course involves daily sessions five days a week for four to six weeks, with the person seated and passive during stimulation.² Effort is a scheduling problem rather than a clinical variable.

The Regulatory Pathways Are Not Comparable

This distinction is invisible on clinic websites and it matters. TMS systems are cleared for named conditions. BrainsWay states that its Deep TMS system has been FDA-cleared for major depressive disorder since 2013, obsessive compulsive disorder since 2018, smoking cessation since 2020 and anxious depression since 2021.³ Each of those is a specific indication supported by a submission.

Biofeedback devices sit in a different regulatory category. Under federal regulation a biofeedback device is defined as an instrument providing a visual or auditory signal corresponding to the status of a patient’s physiological parameters, such as brain wave activity, muscle activity or skin temperature, so that the patient can voluntarily control those parameters. It is a Class II device, classified by that function rather than by any condition it is cleared to treat. The regulation exempts from premarket notification only prescription battery-powered versions indicated for relaxation training and muscle reeducation.⁴

Read those two paragraphs together and the asymmetry is clear. A TMS provider treating depression is operating within a cleared indication for that condition. A neurofeedback provider treating depression is using a device class that carries no clearance naming that condition. That does not make the practice improper, and it does explain why claims in the two fields should be weighed differently and why coverage outcomes differ so sharply.

Non-Response Means Different Things

When a TMS course does not work, the interpretation is relatively clean. The patient received the intervention as intended and did not respond, and the next question is whether to adjust the protocol or change direction.

When neurofeedback does not work, there are two possibilities that look identical from outside. The training may not be effective for this problem, or the client may not have learned the regulation the protocol was trying to teach. Services differ in whether they measure learning separately from symptom change, and asking that question is a fast way to distinguish a rigorous provider from a permissive one.

The Evidence Bases Are Shaped Differently

TMS evidence rests on sham-controlled trials in named conditions, which is what supports the clearances. Neurofeedback evidence is more heterogeneous. A systematic review and meta-analysis of sustained effects in ADHD pooled ten randomized controlled trials and found neurofeedback superior to non-active controls on inattention and on hyperactivity and impulsivity, with effects maintained at follow-up. Active treatment held a significant advantage on inattention at the end of treatment, and that advantage was no longer significant by follow-up.⁵

Superiority over a non-active control is a weaker claim than superiority over a sham, and the adequacy of blinding is the live methodological dispute in neurofeedback research. The honest comparative statement is that TMS has a narrower evidence base tied to specific cleared indications while neurofeedback has a broader and more contested one. Yellowbrick provides neuroscience technologies and neuromodulation services through an agreement with its sister company Synchrony Brain Health, whose outpatient services include both Deep TMS and neurofeedback, and Yellowbrick’s own neuroscience-informed model sits behind that referral, so a candidacy discussion can consider either without the referral being routed by which modality a provider happens to own.

Neurofeedback and TMS Side by Side

How to Explain the Choice to a Client

• Say which one asks something of them, since that is the difference clients grasp fastest.
• Describe neurofeedback as learning a skill with feedback, not as having something done to them.
• Describe TMS as a procedure they attend, and be specific that it is daily on weekdays for several weeks.
• Explain that regulatory status differs, and that a cleared indication is not the same as a device classified for relaxation training.
• Be explicit that not everyone learns to self-regulate, so neurofeedback carries a learning risk as well as an efficacy question.
• Set funding expectations separately for each, since they usually differ.
• Do not present them as interchangeable options at the same level of evidence.
• Say what would count as success, and when that would be reviewed.
• Confirm that either would be added to their current treatment rather than replacing it.
• Leave candidacy to the treating service, and frame the referral as a question rather than a recommendation.

Key Takeaway

The difference is the direction of the intervention. TMS acts on the brain from outside and the patient is passive, while neurofeedback trains the patient to change their own activity and the patient is the active party. Everything else follows. TMS systems carry condition-specific clearances while biofeedback devices are Class II, classified by device function rather than by a treated condition. TMS evidence rests on sham-controlled trials in named indications while neurofeedback evidence is broader and mostly measured against non-active controls. And non-response to neurofeedback may reflect a failure to learn rather than a failure of the method. Match the modality to the client rather than to the diagnosis. A depleted, disengaged client may do better with a procedure they attend than with a skill they must acquire.

Clinical Note

This article is general guidance for referring clinicians. It is not a substitute for individual clinical judgment or an individualized assessment, it does not establish suitability for any intervention and it does not constitute medical, regulatory or coverage advice. Device classifications, clearances and coverage policies vary and change over time. Candidacy and protocol decisions rest with the treating service and the treating physician, and safety screening is conducted separately by that service.

If a client is in immediate danger, direct them to emergency services. The 988 Suicide and Crisis Lifeline provides free, confidential crisis support 24 hours a day, seven days a week, by call or text to 988.⁶

Glossary

• Neuromodulation: an umbrella term covering interventions that alter neural activity, including both direct stimulation and feedback-based training.
• Operant conditioning: learning in which the likelihood of a response changes according to the consequence that immediately follows it.
• Set-point: in neurofeedback, the internal target state a learner establishes and then refines across sessions.
• Class II device: a federal device classification carrying special controls, distinct from a clearance for a specific medical indication.
• Cleared indication: a specific condition a device has been authorized to be marketed to treat.
• Non-active control: a comparison condition involving no active intervention, weaker as a comparator than a sham designed to be indistinguishable from treatment.
• Learning risk: the possibility that a client does not acquire the regulation a feedback-based intervention is designed to teach, which has no direct equivalent in a passively delivered procedure.

References

1. Enriquez-Geppert S, Huster RJ, Herrmann CS. “EEG-Neurofeedback as a Tool to Modulate Cognition and Behavior: A Review Tutorial.” Frontiers in Human Neuroscience, vol. 11, February 2017. Accessed August 25, 2026. https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2017.00051/full.
2. National Institute of Mental Health. “Brain Stimulation Therapies.” NIMH Health Topics, last reviewed March 2024. Accessed August 25, 2026. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.
3. BrainsWay. “Which conditions is Deep TMS officially cleared to treat?” BrainsWay professionals FAQ. Accessed August 25, 2026. https://www.brainsway.com/professionals-faqs/what-mental-health-conditions-is-deep-tms-fda-cleared-to-treat/.
4. U.S. Food and Drug Administration. “21 CFR 882.5050, Biofeedback device.” Code of Federal Regulations, Title 21, Part 882, Subpart F. Accessed August 25, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-882/subpart-F/section-882.5050.
5. Van Doren J, Arns M, Heinrich H, Vollebregt MA, Strehl U, Loo SK. “Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis.” European Child and Adolescent Psychiatry, vol. 28, 2019, pages 293 to 305. Accessed August 25, 2026. https://link.springer.com/article/10.1007/s00787-018-1121-4.
6. 988 Suicide and Crisis Lifeline. Operated in partnership with the Substance Abuse and Mental Health Services Administration and Vibrant Emotional Health. Accessed August 25, 2026. https://988lifeline.org/.

Learn more about Yellowbrick Consultation and Treatment Center on Google.